Mallinckrodt PLC (MNK)

49.56
0.14 0.28
NYSE : Health Care
Prev Close 49.42
Open 49.78
Day Low/High 48.84 / 50.62
52 Wk Low/High 48.61 / 85.83
Volume 667.18K
Avg Volume 2.21M
Exchange NYSE
Shares Outstanding 105.86M
Market Cap 5.36B
EPS 5.80
P/E Ratio 11.54
Div & Yield N.A. (N.A)

Latest News

Eli Lilly and Express Scripts Announce Program to Lower Insulin Prices to Avoid Mylan-Like Uproar

Eli Lilly and Express Scripts Announce Program to Lower Insulin Prices to Avoid Mylan-Like Uproar

Eli Lilly and Express Scripts are seeking to avoid potential bad press over high insulin prices.

Broadcom Call Should 'Make You Feel Better About Owning Apple': More Squawk From Jim Cramer

Broadcom Call Should 'Make You Feel Better About Owning Apple': More Squawk From Jim Cramer

Broadcom released better-than-expected 2016 fourth-quarter results, and its stock on Friday is giving a picture of where the rally could 'broaden to,' says Jim Cramer.

Biotechs Bolstered on 21st Century Cures Passage

Biotechs Bolstered on 21st Century Cures Passage

Biotechs were trading at high volumes Thursday morning on news that the Senate has passed the 21st Century Cures Act.

Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality Index

Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality Index

-- Mallinckrodt Earns Designation as a "Best Place to Work for LGBT Equality" on Human Rights Campaign Foundation's 15th Annual Scorecard on LGBT Workplace Equality --

Mallinckrodt Beats Estimates, Issues Downbeat Guidance

Mallinckrodt Beats Estimates, Issues Downbeat Guidance

Shares of Mallinckrodt were lower on Tuesday, despite posting better than expected fourth-quarter revenue and profits.

Mallinckrodt Shares Tank, Despite Better-Than-Expected Earnings

Mallinckrodt Shares Tank, Despite Better-Than-Expected Earnings

The pharmaceutical company saw shares fall more than 8% Tuesday.

Healthcare Stocks Help Nasdaq Reach New Heights

Healthcare Stocks Help Nasdaq Reach New Heights

The Nasdaq rose 0.7% to an all-time high of 5,403. The S&P 500 was up 0.3%, and the Dow Jones Industrial Average gained 0.2%.

The New #156 Most Shorted S&P 500 Component: Mallinckrodt

The New #156 Most Shorted S&P 500 Component: Mallinckrodt

The most recent short interest data has been released for the 11/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Mallinckrodt Will Initiate Company-Sponsored Clinical Trial Of H.P. Acthar® Gel In Treatment Of Amyotropic Lateral Sclerosis (ALS)

Mallinckrodt Will Initiate Company-Sponsored Clinical Trial Of H.P. Acthar® Gel In Treatment Of Amyotropic Lateral Sclerosis (ALS)

-- Investigational New Drug (IND) Application for use of H.P Acthar Gel in ALS Awarded Fast Track Designation by U.S. FDA --

Clinical Pharmacokinetic And Health Economic Data On OFIRMEV® (Acetaminophen) Injection Presented At 15th Annual Pain Medicine Meeting Of ASRA

Clinical Pharmacokinetic And Health Economic Data On OFIRMEV® (Acetaminophen) Injection Presented At 15th Annual Pain Medicine Meeting Of ASRA

-- Primary Data Show Altered Absorption of Oral Acetaminophen and Increased Variability when Co-Administered with IV Morphine --

Study Addresses Possible Impact Of H.P. Acthar® Gel On Use Of Corticosteroids Among Patients With Rheumatoid Arthritis, Lupus, And Dermatomyositis/Polymyositis

Study Addresses Possible Impact Of H.P. Acthar® Gel On Use Of Corticosteroids Among Patients With Rheumatoid Arthritis, Lupus, And Dermatomyositis/Polymyositis

-- Claims-based, retrospective data unveiled at the 2016 ACR/ARHP Annual Meeting--

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Mallinckrodt Public Limited Company - MNK

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Mallinckrodt Public Limited Company - MNK

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Mallinckrodt Public Limited Company (NYSE:MNK) resulting from allegations that...

Andrew Left: Dump Mallinckrodt

Andrew Left: Dump Mallinckrodt

The famed short-seller says the drug company could face a U.S. government crackdown.

In Case You Missed It: Apple, Google on the Wing

In Case You Missed It: Apple, Google on the Wing

Google announced it will set up a London headquarters. The move follows Apple's decision to shift 1,400 people to London's Battersea Power Station, the backdrop to Pink Floyd's album "Animals."

Citron Research's Left Explains Allegation That Mallinckrodt CEO Committed Fraud

Citron Research's Left Explains Allegation That Mallinckrodt CEO Committed Fraud

Citron Research issued a note Wednesday that accuses Mallinckrodt (MNK) CEO Mark Trudeau of committing fraud.

Clinical Data Analysis On Terlipressin Presented At The Liver Meeting®

Clinical Data Analysis On Terlipressin Presented At The Liver Meeting®

-- Data Show Small Improvements in Serum Creatinine (SCr) Associated with Increased Survival of Hepatorenal Syndrome Type 1 (HRS-1) Patients --

First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel For Lupus

First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel For Lupus

-- Mallinckrodt's Trial Designed to Measure Improvement in Disease Activity --

First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel For Rheumatoid Arthritis

First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel For Rheumatoid Arthritis

-- Mallinckrodt's Trial Designed to Measure Ability to Achieve Low Disease Activity --

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AYR, CRCM, TG Downgrades: ADPT, AMZN, ANGI, ARNC, BKD, BWXT, CAJ, CALX, CSGP, EMR, HZO, LXRX, MNK, MYGN, NTRA, PBI, TCO, TRI Initiations: PFGC Read on to get TheStreet Quant Ratings' detailed report: